Study S000815

A 52 Week Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multi-Center, Multinational Trial In Islet Cell Transplant Subjects With Type 1 Diabetes Mellitus To Determine If The Early Use Of Liraglutide As An Adjunct To Standard Care Increases The Proportion Of Subjects Achieving Insulin Independence After First Transplantation

ClinicalTrials.gov record

Registration

Registration: NCT01206101
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: DOUBLE
Status: TERMINATED
Enrollment: 3
Start: 2012-03-21
Primary completion: 2013-06-03
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 1
Interventions: DRUG:liraglutide; DRUG:placebo
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2009-013090-18; OTHER:U1111-1114-8952; NIH:2009

Registered primary outcomes

Proportion Of Insulin-independent Subjects After Receiving Only One (Single-Donor) Islet Cell Transplant [At week 52 after initial transplantation]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.